(NASDAQ: RCKT) Rocket Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Rocket Pharmaceuticals's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast RCKT's revenue for 2025 to be $5,944,072,682, with the lowest RCKT revenue forecast at $319,889,103, and the highest RCKT revenue forecast at $12,038,493,243. On average, 6 Wall Street analysts forecast RCKT's revenue for 2026 to be $18,055,607,270, with the lowest RCKT revenue forecast at $792,258,678, and the highest RCKT revenue forecast at $57,164,182,706.
In 2027, RCKT is forecast to generate $43,720,310,004 in revenue, with the lowest revenue forecast at $1,957,721,310 and the highest revenue forecast at $63,652,600,012.